Intellectual Property India Publishes Patent Application for 'Anti CD47 Antibodies And Methods Of Use' Filed by Shanghai Henlius Biotech Inc.; Shanghai Henlius Biopharmaceutical Co. Ltd.; and Shanghai Henlius Biologics Co. Ltd.

MUMBAI, India, Nov. 7 -- Intellectual Property India has published a patent application (202527071564 A) filed by Shanghai Henlius Biotech Inc.; Shanghai Henlius Biopharmaceutical Co. Ltd.; and Shanghai Henlius Biologics Co. Ltd., Shanghai, on July 28, for 'anti cd47 antibodies and methods of use.'

Inventor(s) include Baral Toya; and Xu Wenfeng.

The application for the patent was published on Nov. 7, under issue no. 45/2025.

According to the abstract released by the Intellectual Property India: "Provided are antibodies and antibody derivatives that bind to CD47(also known as IAP MER6 and OA3) and methods of using the same. In certain embodiments an anti CD47 antibody or antibody derivate disclosed herein exhibits reduced binding to a red...